Pall Integrated Solutions for Gene Therapy

 

Pall have technologies that enable production of viral vectors on a production scale in a relatively small footprint. The statement holds true for both AAV and lent virus. The talk will cover both upstream and downstream technologies starting with seed train all the way through to the final formulation and filling step. With regards to bioreactors we will cover both adherent cell and suspension cell capabilities and projected future movements in the field. We will touch on process development services (PDS) where Pall are able to bring all of their expertise in continuous intensified process development to shorten the path to market for gene therapies.

Speaker

Rick Morris, Ph.D.

 

Senior Vice President, R&D

Palll Biotech



Dr. Rick Morris has held many senior-level positions within both the Life Sciences and Industrial lines of business at Pall Corporation, gaining experience in the biopharmaceutical, medical, food & beverage and laboratory markets during his 30-year tenure. In September 2017, he was appointed as a senior vice president of R&D for Pall, which combines both single use technologies and biopharmaceutical groups, with a specific focus on the rapidly growing field of continuous bioprocessing. In this role Dr. Morris leads internal and external research and development projects on a global basis. He is based in Westborough, MA, USA and has R&D teams in the USA, UK and Belgium.

Pall Biotech Integrated Solutions for Gene Therapy

Scale Up And Risk Mitigation Of Therapeutic Viral Vectors For Gene Therapy

Register to learn more about scale up and risk mitigation of viral vectors for GT.

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
April 2022
Getting Ready for SUT X-Ray Irradiation

Biotech Research & Commercialization Solutions | Pall Corporation webinar series

Why the introduction of X-ray sterilization technology is a critical change for single-use industry, and how gamma and X-ray irradiation compare

 

The market demand for gamma irradiation, the current primary method for the sterilization in SUT, will soon significantly exceed supply, creating an urgent need for alternatives.

 

Join Christelle Marcoux from GSK Vaccines (BioPhorum workstream member on alternatives to gamma sterilization) and James Hathcock, PhD of Pall Corporation (Bio-Process Systems Alliance X-Ray Committee Co-Chair) as they discuss the introduction of X-ray sterilization technology.

 

You will learn more about:

 

  • Why this is a critical change for industry and the responsibilities of each stakeholder
  • Key questions to address for biomanufacturers
  • How gamma and X-ray irradiation compare
  • What testing has been completed and key milestones for readiness for industry
  • An example of how to qualify a SUS sterilized with X-ray irradiation
Watch